NCT00478608View on ClinicalTrials.gov

Study Evaluating Rapamune® Maintenance Regimen

PHASE3CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Renal Transplant
Interventions
DRUG

Sirolimus (Rapamune®)

(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.

Trial Locations (9)

700-712

Deagu

700-721

Deagu

614-735

Pusan

110-744

Seoul

120-752

Seoul

135-710

Seoul

137-701

Seoul

138-736

Seoul

443-721

Suwon

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00478608 - Study Evaluating Rapamune® Maintenance Regimen | Biotech Hunter | Biotech Hunter